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Abstract
Purpose Malignant tumors of the intra-oral minor salivary
glands are uncommon. The aim of this study was to give
information concerning the clinical features of these
tumors, the distribution of location, treatment opportunities,
and outcome.
Methods Twenty-seven patients with malignant salivary
gland tumors that were treated between January 1999 and
December 2008 were evaluated retrospectively.
Results Of the 27 minor salivary gland carcinomas, 48.1%
were adenoid cystic carcinomas (ACC), 29.7% mucoepi-
dermoid carcinomas (MEC), 22.2% adenocarcinomas
(ADCA). The most common first symptom was a painless
swelling in 60% of the cases, with the second most
common symptom being ulcers (28%). Four recurrences
and two metastases were found. No recurrence was
observed in ADCA. All four patients experiencing a
recurrence developed it in the first 3 years after treatment.
Conclusion Wide excision with a clinical margin of 1 cm
and in large tumors, positive surgical margins or perineural
infiltration and postoperative radiotherapy (RT) can be
recommended; but in order to give exact information
concerning the possible benefit from postoperative RT, it
needs large prospective multicenter studies. Long-term
follow-up controls and in particularly longer than 5 years
in ACC including yearly chest X-rays should be offered to
these patients because of late metastasis and recurrences.
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Introduction
Between 450 and 750 minor glands can be found scattered
throughout the head and neck and are present in many sites,
such as the lips, cheek, gingival, palate, tongue, oropharynx,
parapharyngeal space, and paranasal sinuses [1]. Malignant
tumors of the intra-oral minor salivary glands constitute
2–3% of all malignant neoplasms of the upper aerodigestive
tract and less than 25% of all salivary gland tumors [2].
Tumors arising in major salivary glands due to their well-
defined anatomic borders and their higher incidence cannot
be directly compared to minor salivary gland tumors. Most
tumors arising at minor salivary glands are malignant. The
pathogenesis is still not completely solved, but factors like
smoking, poor mouth hygiene or alcohol abuse seems to
play not the same rule like in oral squamous cell carcinoma.
The most common sites are the hard palate, nasal cavity, and
paranasal sinuses [3]. Squamous cell carcinomas of the oral
cavity are well studied, but malignant tumors of the minor
salivary glands are rare. However, controversy still sur-
rounds several issues including length of follow-up time and
indications for radiotherapy (RT). Most of the studies that
are available are retrospective studies.
The purpose of this study was to determine the
histological types, sites and prognostic factors of patients
with malignant minor salivary gland carcinomas and to
compare the results with data from different reports.
Patients
The records of all patients with malignant minor salivary
gland tumors from January 1999 and December 2008,
treated in the Department of Craniomaxillofacial and Oral
Surgery, University Hospital Zurich were systematically
reviewed for tumor site, histological type, involvement
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of lymph nodes, metastases, treatment, and recurrence.
Exclusion criteria were recurrent disease plus lack of
information, therefore two patients were excluded. In all
patients, an incisional biopsy and computed tomography
(CT), positron-emissions tomography (PET) or magnetic
resonance imaging (MRI) was performed before the definitive
treatment.
Results
Age, sex, primary sites, and kinds of carcinoma
Together, 27 patients with intra-oral minor salivary gland
tumors were treated and evaluated retrospectively. Out of
these 27 patients, 48.1% had an adenoid cystic carcinoma
Fig. 1 Distribution of age
(ACC adenoid cystic carcinoma,
ADCA adenocarcinoma, MEC
mucoepidermoid carcinoma)
ACC ADCA MEC
Number of patients 13 6 8
Age Mean 64.4 47.3 51.1
Minimum 36 35 22
Maximum 87 62 73
Sex Male 6 3 4
Female 7 3 4
Tumor site Upper jaw alveolar ridge 4 2 1
Hard palate 5 2 5
Soft palate 2 2 1
Lower jaw 2 0 1
Tumor status T1 3 2 4
T2 5 3 3
T3 2 0 0
T4 3 1 1
Node status N1 1 0 0
N2a 2 0 0
N2b 0 0 0
N2c 0 0 0
N3 0 0 0
Metastases status M0 0 0 0
M1 1 0 0
Table 1 Tumor location and
stage at initial clinical
presentation
ACC adenoid cystic carcinoma,
ADCA adenocarcinoma, MEC
mucoepidermoid carcinoma
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(ACC), 29.7% a mucoepidermoid carcinoma (MEC), and
22.2% an adenocarcinoma (ADCA). The female to male ratio
was 14:13, and the average age for MEC was 47.9 years (28–
83 years); for ADCA, 47.3 years (35–62 years); and for ACC,
64.4 years (36–87 years). The most common age period for
developing a malignant tumor of the intra-oral minor salivary
gland was between 55 and 70 years (Fig. 1).
The distribution of location is presented in Table 1: in the
region of the alveolar ridge, the most common minor salivary
cancer is ACC; and in the hard palate, it is the MEC. Forty-
four percent of these tumors are located in the hard palate.
Regarding the tumors located in the lower jaw, one ACC was
located on the ascending ramus and one on the alveolar crest
in an edentulous region. One MEC was located on the
alveolar crest in an edentulous region. Figure 2 does give an
overview about the primary location of all included cases.
Initial symptoms and therapy
Most patients were referred from private dentists. The most
common first symptom, found in 60% of patients, was a
painless swelling, followed by an ulcer (28%).
The tumors in the present study were resected clinically
with 1-cm margins. Out of 27 patients, five patients (four
with ACC and one with MEC) had a supraomohyoidal
neck dissection because of clinically positive lymph nodes.
Recurrence, positive lymph nodes, large tumors, or positive
surgical margins were an indication for radio- and/or
chemotherapy (Table 2).
Treatment results and follow-up strategy
In four out of 27 patients, a recurrence (three in ACC and
one in MEC) was observed. No recurrence was observed in
ADCA (Table 2).
All four patients experiencing a recurrence developed it
in the first 3 years after treatment. Two patients were treated
first in a different hospital, so that the original pathohistology
was not available. Five patients (all with ACC) had perineural
infiltration in their first resection, but in only one, recurrence
and metastases developed until now (Table 3). Neck
dissections were only performed in cases of clinically
positive lymph nodes. The median follow-up time for ACC
was 60 months, for ADCA 54 months and for MEC
47.9 months (Table 2). The patients were seen in the first
year on a monthly basis, in the second year every 2 months,
in the third year every 3 months, in the fourth year every
6 months followed by a yearly control (Table 4).
Discussion
In several studies, adenoid cystic carcinoma has been
shown as being most common [4–6], with several other
studies showing, on the other hand, that mucoepidermoid
carcinoma is the most common (Table 5) [2, 7–10]. Some
authors describe the tumor distribution pattern as varying
by country.
Most reports describe a female predominance in minor
salivary gland tumors [4, 5] similar to the proportion in the
present study, which shows female to male as 7:6. The main
age group was found between 60–79 years; that is also
supported in other studies [11, 12]. Also, the present study
shows the palate as the predominant location (62.9% in the
hard and soft palate), a finding comparable to those of other
current studies [4, 5, 10]. Concerning recurrence, only a
very few studies are available because of late metastasis,
older age of patients, and lower incidence of these tumors.
A lower rate of cervical lymph node metastases in
comparison to oral squamous cell carcinomas has been
reported by several authors [1, 13] and this was also
supported by the present study; in only three out of 27
patients were positive lymph nodes found. Therefore, there
is probably little benefit from elective neck dissection. In
this study, neck dissection was performed in patients withFig. 2 Tumor locations
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clinical or radiological suspect of lymph node metastasis or
in patients with T4 tumor stage.
Regarding the initial therapy, there was no difference
between the patients developing recurrence (Table 3) on the
one hand and the patients not experiencing recurrence on
the other hand.
Further therapy strategies recommend on a type-2 level
of evidence [14] in cases of unresectable/inoperable locore-
gional disease neutron, heavy ions or proton radiotherapy.
But there are still controversies concerning radiotherapy, on
the one hand surgical resection and postoperative RT is
recommended [15]. But on the other hand, Spiro et al.
could not show a survival benefit for patients receiving
postoperative RT, after matching for stage, site, and
histology [12].
Concerning neutron beam, one problem seems to be the
limited number of institutions providing this treatment
besides the reported complication rate like osteroradionec-
rosis, optic neuritis/retinitis, and oral/pharyngeal-cutaneous
fistulas [14, 16].
Due to overlapping clinicopathological features of ACC
and polymorphous low-grade adenocarcinoma (PLGA), the
differentiation can be difficult. Up until now, only vimentin
presents a clear difference, which is negative in ACC and
Table 3 Patients with recurrence and/or metastases
Patient Tumor
type
TNM Perineural
infiltration
Recurrence Metastases Outcome Follow-up
time
Initial Therapy
1 ACC T2N2bM0 Yes 32 months 44 months DOD 48 months Tumor resection with free margins,
unilateral neck dissection due to
known lymph node metastasis, no
extracapsular tumor cells
2 ACC T2N0M0 No None 68 months Palliative 74 months Tumor resection with free margins,
no neck dissection due to no sign of
lymph node metastasis in clinical
and radiological examination
3 ACC T4N0M0 No 34 months None Tumor free 110 months Tumor resection with R1 margins,
postoperative radiotherapy, neck
dissection due to T4 state despite no
clinical or radiological signs of
lymph node metastasis, neck
dissection revealed no lymph node
infiltration
4 MEC T4N0M0 No 14 months None Tumor free 42 months Tumor resection with free margins,
neck dissection due to T4 state
despite no clinical or radiological
signs of lymph node metastasis,
neck dissection revealed no lymph
node infiltration
ACC adenoid cystic carcinoma, DOD death of disease, MEC mucoepidermoid carcinoma
Table 2 Treatment strategies and outcome
ACC ADCA MEC
Follow up period (in months) Mean 60 54 47.9
Minimum 27 28 28
Maximum 110 67 83
Recurrence 3 0 1
Metastases 2 0 0
Treatment Resection only 7 5 8
Resection & Neck dissection 1 1 0
Resection & Radiotherapy 1 0 0
Resection & Neck dissection & Radiotherapy 3 0 0
Radiotherapy alone 1 0 0
ACC adenoid cystic carcinoma, ADCA adenocarcinoma, MEC mucoepidermoid carcinoma
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positive in PLGA. CEA, EMA, and S100 protein can be
positive in both tumors [17]. Concerning salivary gland
tumors, Ki-67 has been discussed as a prognostic factor
because of being significantly higher in cases of treatment
failure and large tumors [18], but in clinical routine, the
application of Ki-67 is still missing.
Adenoid cystic carcinoma
The peak incidence of these tumors was between 60 and
79 years, although the literature describes a wide age
distribution [18]. Also, the predominance of females, as in
our study, is confirmed (7:4). Nearly half of all intra-oral
ACC occur in the palate [17].
The growth pattern of ACC is described as slow but
aggressive, with a predominantly perineural spread and less
lymphatic spread, but also with more frequent distant
metastasis (particularly in the lungs) after long-term
survival and even in the absence of local or regional
recurrence [19]. Therefore, it is difficult to distinguish
between recurrence and a second tumor in adenoid cystic
carcinomas. Distant metastases, when affecting the lungs,
are usually slow growing, sometimes apparently isolated,
and frequently surgically resectable [20]. The longest time
elapsing before a distant metastasis in the present study was
68 months.
Compared to other head and neck malignancies, ACC are
more difficult to clear surgically, often resulting in positive
margins [17]. In the present study, only in one case was a
second resection performed immediately after histopatholog-
ical diagnosis of involved margin (not detected in frozen
section), this patient showed no recurrence or metastases.
Predictors for distant metastasis seem to be large tumor
size and lymph node involvement [21]. Therefore, initial
aggressive surgery, combined with radiation for high-stage
tumors or involved surgical margins, is suggested [18, 21].
These principles were also used in the present study.
Mucoepidermoid carcinoma
MEC was indicated in 32% of the cases as the second most
common type of tumor. The female to male ratio was 1:1.
In contrast to ACC, MEC show their malignant behavior
within the first 5 years after surgery [18, 22]. In only one
Author Year N ACC ADCA MEC others
Vander Poorten et al. [11] 2000 55 22 5 9 16
Jansisyanont et al. [29] 2002 61 7 9 33 9
Strick et al. [1] 2004 21 7 6 6 2
Toida et al. [5] 2005 27 10 0 8 6
Yih et al. [10] 2005 94 22 18 45 8
Pires et al. [32] 2007 241 35 28 125 32
Buchner et al. [7] 2007 156 24 27 83 16
Copelli et al. [33] 2008 43 26 1 12 2
Mücke et al. [34] 2009 95 33 14 20 28
Table 5 Studies emphasized on
malignant minor salivary gland
tumors
ACC adenoid cystic carcinoma,
ADCA adenocarcinoma, MEC
mucoepidermoid carcinoma
Table 4 Treatment and follow-up strategy
ACC MEC ADCA
Resection alone Negative lymph nodes Negative lymph nodes Negative lymph nodes
Additional neck dissection Positive lymph nodes Positive lymph nodes Positive lymph nodes
Additional radiotherapy Lymph node metastases Lymph node metastases Lymph node metastases
R1 resection R1 resection R1 resection
Recurrent cancer Recurrent cancer Recurrent cancer
High-grade malignancy High-grade malignancy High-grade malignancy
Perineural invasion Perineural invasion Perineural invasion
Radiotherapy alone Unresectable tumors Unresectable tumors Unresectable tumors
Follow-up time including At least 20 years At least 5 years At least 5 years
Clinical control
CT or MRI
Yearly chest X-rays
ACC adenoid cystic carcinoma, ADCA adenocarcinoma, MEC mucoepidermoid carcinoma
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case out of eight was a recurrence seen after 14 months and
resected again. An increase of Ki-67 has been discussed in
order to differentiate between malignant and benign gland
tissue [18, 23] but has not been established in clinical
routine to date. Although radio-resistance is discussed,
radiation is recommended in patients with positive surgical
margins and high-grade tumors [15, 24]. Tran et al. reported
an improvement of local control by RT in patients with
positive surgical margins from 50% to 71% [25]. Recurrence
of MEC appears mostly in the first 5 years after surgery [18].
Adenocarcinoma
A predominance in female patients was also described by
Pogodzinski et al. [26]. No recurrence was found in the
patients in the present study but delayed local recurrences
and regional nodal metastases have been mentioned in the
literature [26–28]. In contrast to adenoid cystic carcinoma,
adenocarcinoma has an excellent cure rate after complete
excision infrequent recurrences and rare regional metastasis
[29]. In the present study, no recurrence or metastasis was
observed in this patient group.
Limitations
The main weakness of this study was the small number of
patients. Within the limitations of this investigation, the
results show the need of long follow-up times in patients
with ACC. Also, there were considerable differences in the
surgical and postoperative follow-up protocols, as well as in
the length of follow-up time. Most of those protocols suffer
from a lack of long-term results: most studies cover less
than 5 years of postoperative controls; and, due to the
higher age of this patient group, long-term controls are not
always possible.
Therapy
Postoperative RT should be recommended for patients with
high-grade malignancies, lymph node metastases, perineural
invasion, and recurrent cancer. It is mentioned that RT alone
can cure patients with minor salivary gland malignancy, but
the overall survival rates are lower compared to RT in
combination with surgery [3].
Prognosis
Concerning prognosis, one must differ between oral and
paranasal sinus malignancies, the latter seems to be
associated with advanced-stage lesions, bone invasion,
nerve involvement, adenoid cystic carcinoma, and positive
margins [30]. Probably, in these cases, one should consider
proton beam RT in order to reduce complications associated
with central nervous system or visual apparatus.
Vander et al. and Spiro et al. recommend that the oral
squamous cell carcinoma TNM classification as one of the
major prognostic factor for all oncologic outcomes after
diagnosis of minor salivary gland carcinoma [11, 12]. Our
small study indicated that perineural infiltration is not
directly associated with distant metastases, but for exact
evaluation it needs larger and longer studies.
Seventy percent of local recurrences are observed within
3 years. But there is a clear exception in cases of high-grade
and adenoid cystic histology [31]. Therefore, along with
Guzzo et al., we recommend a follow-up period of 20 years
in particular in adenoid cystic carcinomas or high-grade
tumors including yearly chest X-rays.
Conclusion
Wide excision with a clinical margin of 1 cm and in large
tumors, positive surgical margins or perineural infiltration
additional postoperative radiotherapy can be recommended.
But in order to give exact information concerning the
possible benefit from postoperative radiotherapy, it needs
large prospective multicenter studies. Long-term follow-up
controls and in particularly longer than 5 years in adenoid
cystic carcinomas including yearly chest X-rays should be
offered to these patients because of late metastasis and
recurrences.
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